How much is a cnbx stock worth?
One share of CNBX stock can currently be purchased for approximately $0.16. How many employees does Cannabics Pharmaceuticals have? Cannabics Pharmaceuticals employs 11 workers across the globe.
Is Cannabics Pharmaceuticals the right stock to buy now?
Wall Street analysts have given Cannabics Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cannabics Pharmaceuticals wasn't one of them.
How can parties contact Cannabics Pharmaceuticals (cnbx)?
Parties interested in contacting Cannabics Pharmaceuticals, CNBX, should contact CEO Eyal Barad at [email protected].
What is the CNBX?
What is the CNBX patent?
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program using Psylocibin and Psilocin. The announcement comes after the company was able to obtain a license from the Israeli Ministry of Health to conduct scientific research using Psylocibin and Psilocin in the company's in-house laboratory facilities in Rehovot, Israel.
What is CNBX in medical?
(OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the company's patent titled: "System and Method for High Throughput Screening of Cancer Cells" has been granted by the European Patent Office.
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program for the development of a Breast Cancer antitumor targeting medicine.
Cannabics Pharmaceuticals (OTCMKTS:CNBX) Frequently Asked Questions
Cannabics Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer. The company was founded by Eyal Barad on September 15, 2004 and is headquartered in Bethesda, MD.
